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DBackground: Neonatal cardioplegic arrest is associated with apoptosis-related mitochondrial dysfunction, in-
cluding Bax translocation to the mitochondria, mitochondrial permeabilization, cytochrome c release, and elec-
tron transport chain dysfunction. We sought to characterize the time course and mode of postcardioplegic
mitochondrial membrane permeabilization and hypothesize that permeabilization is transient and mediated
by the mitochondrial permeability transition pore.
Methods: Isolated, perfused neonatal rabbit hearts underwent 60 minutes of warm crystalloid cardioplegic ar-
rest followed by 120 minutes of reperfusion. Mitochondrial permeabilization was evaluated by means of infu-
sion of 2-deoxy [3H] glucose and subsequent detection of entrapment in isolatedmitochondrial fractions. Groups
included preloading with 2-deoxy [3H] glucose followed by cardioplegia and reperfusion (CCP), cardioplegia
and cyclosporin A (specific inhibitor of mitochondrial permeability transition pore opening; CCPþCsA) or
HA14-1 (Bcl-2 inhibitor; CCPþHA), and noncardioplegia control hearts (non-CCP). Reconstitution of mito-
chondrial integrity was tested bymeans of delayed infusion of 2-deoxy [3H] glucose 30minutes after reperfusion
(P-CCP).
Results:Cardioplegic arrest was associated with mitochondrial permeability transition pore opening, Bax trans-
location, cytochrome c release, radical oxygen species production, and electron transport chain dysfunction. In-
hibition of mitochondrial permeability transition pore opening by cyclosporin A ameliorated this response,
whereas inhibition of Bcl-2 exacerbated these changes. Postreperfusion entrapment of 2-deoxy [3H] glucose
was significantly reduced in comparison with that seen in CCP hearts, suggesting that closure of the mitochon-
drial permeability transition pore ensues within 30 minutes after reperfusion.
Conclusions: Apoptosis-related mitochondrial dysfunction in postcardioplegic neonatal hearts is mediated by
mitochondrial permeability transition pore opening, which is transient and associated with deficits in electron
transport. Clinical strategies directed to minimize mitochondrial permeability transition pore opening are likely
to improve postoperative myocardial dysfunction after neonatal cardiac surgery. (J Thorac Cardiovasc Surg
2011;141:975-82)As a critical mediator in apoptosis signaling pathways, mi-
tochondria integrate upstream death stimuli and undergo
structural and functional remodeling, with subsequent
transmission of apoptotic signals to downstream execu-
tioner proteins.1 After protected ischemia (cardioplegic ar-
rest) and reperfusion, we previously reported a constellation
of apoptosis-related alterations, including Bax transloca-
tion, mitochondrial outer membrane permeabilization,
cytochrome c release, and deficits in electron transport in
the postoperative myocardium.2 These alterations, collec-
tively termed apoptosis-related mitochondrial dysfunction,e Division of Cardiovascular Surgery, Hospital for Sick Children, Labatt
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The Journal of Thoracic and Caare detectable within hours of cardioplegic arrest and are
associated with deficits in global myocardial performance
in laboratory models2,3 and might contribute to the
postoperative myocardial dysfunction observed in
neonatal patients after cardiac surgery.4 Because of the
close interplay between mitochondrial structure and energy
production,5 preservation of mitochondrial architectural
and functional integrity is an important cardioprotective
strategy in the postoperative neonatal heart.3
The mitochondrial permeability transition pore (MPTP)
is a nonspecific pore spanning the inner and outer mitochon-
drial membrane, and its opening during reperfusion results
in impairment of mitochondrial integrity and, under some
circumstances, cell death.6 Depending on the extent of is-
chemia–reperfusion injury, MPTP opening is subclassified
into transient opening or irreversible, long-lasting opening,
and the duration of MPTP opening is a mediator of cell fate
(apoptosis vs necrosis),7 which corresponds to cardiac per-
formance (reversible vs irreversible cardiac functional re-
covery). We have previously demonstrated that selective
inhibition of MPTP opening after cardioplegic arrest leadsrdiovascular Surgery c Volume 141, Number 4 975
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Dto improved preservation of myocardial performance after
reperfusion.3
Bax typically resides in the cytoplasm and is a strongly
proapoptotic member of the Bcl-2 family. Bax activity is op-
posed by Bcl-2, an antiapoptotic member of the Bcl-2 fam-
ily. Overexpression of Bax is associated with an exaggerated
response to ischemia–reperfusion injury.8 After an apoptotic
stimulus, Bax translocates from the cytoplasm to the mito-
chondria and participates in MPTP-mediated mitochondrial
permeabilization.9 MPTP opening can be initiated with non-
specific stimuli associated with reperfusion (eg, oxidative
stress or high calcium concentrations), and the permeabili-
zation stimulus can then be further enhanced through partic-
ipation of Bax.6 In contrast, other investigators have
demonstrated that Bax oligomers have pore-forming capac-
ity, which is independent of MPTP inhibition with cyclo-
sporin A (CsA).10 Thus the roles of the MPTP and Bax in
postreperfusion mitochondrial permeabilization are incom-
pletely defined but important mediators of mitochondrial
permeabilization after ischemia–reperfusion injury.
Because mitochondrial permeabilization is associated
with diminished postoperative global myocardial perfor-
mance, which typically recovers in the early postoperative
period,4 we hypothesized that the MPTP opening is a critical
and transient event in apoptosis-related mitochondrial dys-
function. We tested this hypothesis in a neonatal cardiac
model of cardioplegic arrest using 2 agents that target the
MPTP:CsA,which is known to ameliorate reperfusion injury
in vitro and in vivo in animal models by means of specific in-
hibition of MPTP opening,11,12 and HA14-1, a promoter of
mitochondrial permeabilization that selectively inhibits
Bcl-2, an antiapoptotic protein associated with inhibition of
MPTP opening.13 The interaction of these agents with the
MPTP was evaluated by using the radioactive probe 2-deoxy
[3H] glucose ([3H] DOG), which enters and is trapped in the976 The Journal of Thoracic and Cardiovascular Surgmitochondria when theMPTP undergoes reversible opening,
with the overall objective to gain insights into the time course
of MPTP opening after cardioplegic arrest.MATERIALS AND METHODS
Experimental Model
New Zealand white neonatal rabbits (age, 6 days; weight, 150–200 g)
were anesthetized with sodium pentobarbital (25mg/kg administered intra-
peritoneally), anticoagulated with heparin (1000 U/kg administered intra-
peritoneally), and ventilated. The aorta was cannulated and the heart was
retrogradely perfused in situ to avoid ischemia. The heart (net weight, ap-
proximately 1 g) was then excised, mounted on a Langendorff apparatus,
and perfused at 75 mm Hg perfusion pressure with Krebs–Henseleit buffer
(KHB; 118 mmol/L NaCl, 2.1 mmol/L NaHCO3, 1.2 mmol/L KH2O4, 4.7
mmol/L KCl, 1.2 mmol/LMgSO4, 1.8 mmol/L CaCl2, and 11 mmol/L glu-
cose). Perfusate was filtered with a 4-mm filter, equilibrated with 95% O2
and 5% CO2 at 37
C, and adjusted to a pH of 7.35 to 7.4.
All animals received humane care in compliance with the ‘‘Guide for
the care and use of laboratory animals’’ prepared by the Association for As-
sessment and Accreditation of Laboratory Animal Care (March 1999).
Experimental Protocol
After a 15-minute flow-through period for stabilization, hearts were per-
fused in recirculation mode with 200 mL of KHB containing 1 mmol/L
[3H] DOG (0.2 mCi1) for 30 minutes. Perfusion was then switched back
to flow-through mode with normal KHB for 10 minutes, followed by crys-
talloid cardioplegic arrest for 1 hour (70 mL/kg Plegisol; Hospira, Inc,
Lake Forest, Ill) at 37C and 120 minutes of reperfusion (Figure 1). For
CsA-treated hearts (CCPþCsA group, n¼ 6), CsA (0.2 mmol/L) was added
to the KHB during the stabilization period, as previously described.3 For
HA14-1–treated hearts (CCPþHA group, n ¼ 6), HA14-1 (20 mmol/L)
was administered 10 minutes before cardioplegic arrest, as previously de-
scribed.13 Control hearts included hearts undergoing cardioplegic arrest
and hearts that were perfused but did not undergo cardioplegic arrest.
Cardioplegic control hearts were perfused with KHB and vehicle (0.01%
dimethyl sulfoxide) without either drug and underwent identical periods
of cardioplegic arrest and reperfusion (CCP group, n¼ 6). Noncardioplegic
control hearts (non-CCP group, n ¼ 6) were preloaded with [3H] DOG
without cardioplegic arrest and underwent uninterrupted perfusion. To
assess late opening of the MPTP, another set of control hearts underwent
cardioplegic arrest using the same protocol with the exception that they
were loaded with [3H] DOG 30 minutes after reperfusion in recirculation
mode followed by another 60 minutes of flow-through perfusion with
KHB (postloading control [P-CCP] group, n ¼ 6). At the end of all exper-
iments, ventricular tissue was weighed and immediately fractionated for
subsarcolemmal mitochondrial (SSM) assessment followed by mitochon-
drial functional assessment and MPTP opening measurement.
Mitochondrial Isolation
Whole ventricular tissue was used for SSM isolation, as described by
Palmer and colleagues.14 SSM were specifically examined because previ-
ous reports have demonstrated that SSM are more sensitive to ischemia–
reperfusion injury than interfibrillar mitochondria and are postulated to
be more sensitive mediators of the mitochondrial interaction with reperfu-
sion injury mechanisms within the myocyte.15 The ventricular tissue was
weighed, minced in buffer A (100 mmol/L KCl, 50 mmol/L 3-morpholino-
propane-1-sulfonic acid (MOPS), 1.0 mmol/L MgSO4, 1.0 mmol/L ethyl-
eneglycol-bis-(b-aminoethylether)-N,N,N0,N0-tetraacetic acid [EGTA],
and 1 mmol/L adenosine triphosphate [pH 7.4]) at 4C, and then homoge-
nized in buffer A with 0.2% bovine serum albumin followed by 2 loose
strokes with a Potter–Elvejhem homogenizer. The homogenate was centri-
fuged at 500g, and the supernatant was saved and combined with theery c April 2011
FIGURE 1. Experimental design showing time course of perfusion of isolated hearts in the noncardioplegia control (non-CCP), preloading with 2-deoxy
[3H] glucose followed by cardioplegia and reperfusion (CCP), cardioplegia and cyclosporin A (CCPþCsA), cardioplegia and HA14-1 (CCPþHA), and
delayed infusion of 2-deoxy [3H] glucose 30 minutes after reperfusion (P-CCP) groups. 3H-DOG, 2-Deoxy (3H) glucose.
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Dsupernatant from the second spin after the pellet was resuspended. The
pooled supernatant was centrifuged at 3000g to sediment SSM, which
was washed twice and resuspended in KME buffer (100 mmol/L KCl, 50
mmol/L MOPS, and 0.5 mmol/L EGTA).
Mitochondrial Permeabilization and Cytochrome c
Content
The integrity of the mitochondrial outer membrane was assessed by
measuring the boost of oxygen consumption of mitochondrial complex
IV after administration of exogenous cytochrome c into the respiratory
chamber. The subsequent increase in complex IV activity reflects the per-
meabilization of the outer mitochondrial membrane.16
Mitochondrial cytochrome c content was determined by using the Agi-
lent 8453 UV-visible Spectrophotometer (Agilent Technologies, Wald-
bronn, Germany) with dual-cuvette methods, as described by William.17
Each cuvette contained 0.5 mg of mitochondria solubilized in 5% deoxy-
cholate in 10 mmol/L sodium phosphate (pH 7.0). The oxidized cuvette
contained 5 mmol/L potassium ferricynaide, and the reduced cuvette con-
tained 5 mmol/L ascorbate, to which several grains of sodium dithionate
were added. The cytochrome c content was determined by the difference
of oxidized and reduced spectra and standardized by means of mitochon-
drial citrate synthase (CS) activity.
Mitochondrial Oxygen Consumption Measurement
Isolated mitochondrial oxygen consumption was measured in buffer
containing100 mmol/L KCl, 50 mmol/L MOPS, 1.0 mmol/L EGTA,
5.0 mmol/L KH2PO4, and 5% defatted bovine serum albumin at 30
C
by using a Clark-type electrode (Instech Laboratories, Inc, Plymouth,
Pa). As shown in Figure 2, mitochondrial respiratory state 2 and state 3
for complexes I, II, and IV were measured in the presence of sequential
administration of substrates and inhibitors (glutamate and malate for com-
plex I, rotenone and succinate for complex II, and antimycin, N,N,N0,N0-
tetramethyl-p-phenylenediamine, and ascorbate for complex IV) added in
the following order and final concentrations: 2.5 mmol/L glutamate and
2.5 mmol/L malate, 1 mmol/L lower dose of adenosine diphosphate,
2 mmol/L higher dose of adenosine diphosphate, 2 mmol/L rotenone, 5
mmol/L succinate, 1mmol/L antimycin A, 1 mmol/L ascorbate, and
0.4 mmol/L N,N,N0,N0-tetramethyl-p-phenylenediamine). Mitochondrial
respiratory activity was expressed as the amount of oxygen (nanomoles)The Journal of Thoracic and Caconsumed per minute per milligram of mitochondrial protein. Mitochon-
drial complexes I, II, and IV respiratory control ratios were expressed as
follows: state 3/state 2. The voltage signal was amplified and digitized
by using PowerLab/4sp (AD Instruments, Inc, Colorado Springs, Colo).
All the substrates and inhibitors were purchased from Sigma–Aldrich
(St Louis, Mo).
In Situ Measurement of MPTP Opening
As described previously,18 hearts were homogenized, and samples of
crude ventricular homogenate and mitochondria were assayed for tritium
([3H]). The CS activity of mitochondrial fraction was measured.Mitochon-
drial entrapment of [3H] DOG 6-phosphate was expressed as
105 3 (Mitochondrial [3H] dpm per unit of CS)/(Total heart [3H] dpm
[g wet weight]). In this calculation CS activity is used to correct for varia-
tions in the recovery of intact mitochondria, and the total homogenate [3H]
takes into account differences in loading of hearts with [3H] DOG
6-phosphate between experiments.
CS Activity Assay
SSM (100 mg) was dissolved in 5% cholate and diluted to 100 mL with
KME buffer to make the SSM mixture. The CS activity measurement was
performed in a 1-mL reaction buffer containing 1 mg of SSM mixture,
0.1 mmol/L 5,50-dithio-bis (2-nitrobenzoic acid), 0.4 mmol/L acetyl coen-
zyme A, and 0.5 mmol/L oxaloacetic acid (OAA) at 37C. The increase of
absorbance at 412 nm caused by the CS activity was recorded with an Agi-
lent 8453 UV-visible Spectrophotometer (Agilent Technologies) every 5
seconds for 2 minutes before and after addition of OAA. The absorbance
rate change per minute (Delta A-412 nm/min) was calculated by the sub-
traction of the Delta A-412 nm/min after adding OAA from the Delta
A-412 nm/min before adding OAA. One unit of CS activity was calculated
by using the ratio of Delta A-412 nm min1 to extinction coefficient (13.6).
Detection of Mitochondrial Reactive Oxygen Species
Production
The method for reactive oxygen species (ROS) measurement was de-
scribed by Korge and associates.19 Briefly, malate/glutamate (2.5 mmol/
L each)–energized SSM was incubated in mitochondrial respiratory buffer
with 10 mmol/L CM-H2DCF diacetate (Molecular Probes, Eugene, Ore) at
room temperature for 30 minutes. ROS production was monitored fromrdiovascular Surgery c Volume 141, Number 4 977
FIGURE 2. Representative trace of mitochondrial oxygen consumption in
complexes I,II, and IVand before and after administration of exogenous cy-
tochrome c. ADP, Adenosine diphosphate.
Congenital Heart Disease Leung et al
C
H
Dreduced dichlorofluorescin oxidation (excitation/emission, 490/525) with
a microplate spectroflurometer (Spectra MAX Gemini EM; Molecular
Devices, Sunnyvale, Calif).
Mitochondrial Bax and Bcl-2 Content
Mitochondrial Bax and Bcl-2 concentrations were examined by means
of Western blotting of mitochondrial protein fractions. Briefly, proteins
were electrophoresed in 10% sodium dodecylsulfate–polyacrylamide
gels, transblotted to nitrocellulose membrane, and probed with anti-
rabbit Bax (N-20, 1:1000 dilution; Santa Cruz Biotechnology, Santa
Cruz, Calif) and anti-rabbit Bcl-2 (N-19, 1:1000 dilution, Santa Cruz Bio-
technology). For protein-loading controls, the membranes were stripped
and reprobed with anti-mouse cytochrome c oxidase subunit IV
(1:10,000 dilution, Molecular Probes). Secondary antibodies were coupled
to horseradish peroxidase (anti-mouse IgG, 1:5000 dilution, and anti-rabbit
IgG, 1:1000 dilution, Santa Cruz Biotechnology). The resulting autoradio-
graphs were scanned and quantified. The amounts of mitochondrial Bax
and Bcl-2 were normalized by cytochrome c oxidase subunit IV to control
for variation in mitochondrial protein loading.
Statistics
Data are expressed as means  standard deviations. Planned compari-
sons between 2 groups were made with t tests, as specified. Multiple-
group comparisons were made with analysis of variance with Tukey’s
test for post hoc comparisons, unless otherwise specified.978 The Journal of Thoracic and Cardiovascular SurgRESULTS
Mitochondrial Permeabilization and Cytochrome c
Retention
Cardioplegic arrest and reperfusion were associated with
a deficit of complex IVactivity in CCP and CCPþHA hearts
when compared with that seen in non-CCP hearts (2.13 
0.19 and 1.91  0.25 vs 2.88  0.22 mmol O2 $ min1 $
mg1; P<.02 and P<.01, respectively), and the complex
IV deficit was minimized in CsA-treated hearts (Figure 3,
A). After administration of exogenous cytochrome c, the
deficit of complex IVactivity in CCP and CCPþHA hearts
was reversed, and no significant differences in complex IV
activity were found among the non-CCP, CCP, CCPþCsA,
and CCPþHA groups, indicating that cardioplegic arrest is
associated with mitochondrial permeabilization and cyto-
chrome c–dependent reversible deficits in complex IVactiv-
ity (P>.79 for all comparisons).
Complex IV activity with and without administration of
exogenous cytochrome c can be compared as a ratio and
used to assess the extent of mitochondrial permeabilization.
If the ratio is 1, then exogenous cytochrome c has no effect,
and there is no evidence of outer mitochondrial membrane
permeabilization. Ratios greater than 1 suggest that exoge-
nous cytochrome c boosts electron transport, and the mag-
nitude of the boost correlates with outer mitochondrial
membrane permeabilization.16 The cytochrome c boost
was greater in CCP and CCP þ HA hearts than in non-
CCP and CCP þ CsA hearts (1.81  0.317 and 1.85 
0.297 vs 1.123  0.078 and 1.269  0.071, respectively;
P<.01 all comparisons). There was no significant differ-
ence between CsA and Non-CCP mitochondria (P ¼ .68;
Figure 3, B).
After cardioplegic arrest, cytochrome c was released
from the intermembrane space into the cytosol, and the
mitochondrial content of cytochrome c was reduced. In
comparison with non-CCP mitochondria, cytochrome c
content in CCP and CCP þ HA mitochondria was lower
(108.2  8.1 and 100.8  7.0 vs 161  11.1 pmol $ CS
unit1 $ mg1 protein; P< .01 respectively; Figure 3, C),
and CsA-treated mitochondria had better preservation of
cytochrome c than CCP mitochondria (136.7  15.7 vs
108.2  8.1 pmol $ CS unit1 $ mg1 protein, P<.01).In Situ Measurement of MPTP Opening
Cardioplegic arrest and reperfusion resulted in increased
MPTP opening, which was evident in the higher entrapment
of [3H] DOG in CCP hearts compared with that seen in non-
CCP hearts (67.12 11.59 vs 22.88 8.63 dpm $ CS unit1
$ g1 wet weight, P< .03, Figure 4). Mitochondrial [3H]
DOG entrapment was diminished in CCPþCsA hearts com-
pared with that seen in CCP hearts (36.77 7.71 vs 67.12
11.59 dpm $ CS unit1 $ g1 wet weight, P ¼ 0.03 by using
Fisher’s least significant difference test and P ¼ .18 byery c April 2011
FIGURE 3. A, Mitochondrial complex IVactivity before the addition of exogenous cytochrome c to isolated mitochondria. *P<.02 and **P<.01 versus
the non-CCP group. B, Fold increase of complex IV activity after addition of exogenous cytochrome c. *P<.01 versus the non-CCP group and #P<.01
versus the CCPþCsA group. C, Mitochondrial cytochrome c retention. *P<.01 versus the non-CCP group and #P<.01 versus the CCP group. For def-
initions of the study groups, see the legend for Figure 1.
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compared with CCP hearts (105.12  47.83 vs 67.12 
11.59 dpm $ CS unit1 $ g1 wet weight, P ¼ .06).
To test whether the MPTP opening in CCP hearts is tran-
sient or long lasting, [3H] DOG was loaded after hearts had
been reperfused for 30 minutes, as previously described by
Javadov and coworkers.18 [3H] DOG entrapment in the P-
CCP hearts was significantly reduced compared with [3H]
DOG entrapment in the CCP hearts (36.77  7.71 vs
67.12  11.59 dpm $ CS unit1 $ g1 wet weight,
P<.05). The [3H] DOG entrapment data indicated that car-
dioplegic arrest and reperfusion induced MPTP opening,
which was a transient event, and restoration of mitochon-
drial integrity was nearly complete after 30 minutes of
reperfusion.
Mitochondrial Oxygen Consumption
The deficit in state 3 respiration for complex I was greater
in the mitochondria of CCP and CCPþHA hearts comparedThe Journal of Thoracic and Cawith that seen in non-CCP hearts (1439  446 and 851 
381 vs 1978  279 nmol O2 $ min1 $ mg1 protein;
P ¼ .059 and P< .01, respectively; Table 1). The deficit
in the state 3 respiration for complex IV was also present
in the mitochondria of CCP and CCPþHA hearts compared
with that seen in non-CCP hearts (2127  626 and 1907 
390 vs 2876 222 nmol O2 $min1 $mg1 protein; P<.02
and .01, respectively). Deficiency of state 3 respiration for
complex II was only identified in CCP þ HA hearts
(456  166 nmol O2 $ min1 $ mg1 protein in CCPþHA
hearts vs 648  65 nmol O2 $ min1 $ mg1 protein in
non-CCP hearts, P<.05). These deficits were minimized
in the CCP þ CsA hearts, although the protective effect
was greatest with complexes I and IV. Cardioplegic arrest
and reperfusion decreased the complex I respiratory control
ratio in the mitochondria of CCP hearts compared with that
seen in non-CCP hearts (6.13  2.45 vs 12.36  2.07,
P<.01, Table 2), whereas the decrease in CCP hearts was
significantly reversed in CCPþCsA hearts (16.34  9.93rdiovascular Surgery c Volume 141, Number 4 979
FIGURE 4. Subsarcolemmal mitochondrial entrapment of 2-deoxy (3H)
glucose ([3H] DOG). #P<.03 versus the non-CCP group and *P ¼ .03,
**P<.05, and ***P ¼ 0.06 versus the CCP group. For definitions of the
study groups, see the legend for Figure 1.
TABLE 2. Mitochondrial respiratory control ratio (state 3/state 2)
Groups Complex I Complex II Complex IV
Non-CCP 12.36  2.07 4.08  0.74 18.34  4.21
CCP 6.13  2.45* 2.50  0.45 9.19  2.22y
CCPþCsA 16.33  9.93z 5.15  3.25x 24.54  16.19z
CCPþHA 4.09  1.93 2.17  0.74z 9.24  1.70
Values are presented as means  standard deviations (n ¼ 6 for each group). For
definitions of the study groups, see the legend for Figure 1. *P<.01 and yP<.05
versus the non-CCP group. zP< .05 versus the CCP group. xP ¼ .07 versus the
CCPþHA group.
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ratio was also decreased in CCP hearts compared with that
seen in non-CCP hearts (9.19  2.22 vs 18.34  4.21,
P< .05), whereas the decrease was significantly reversed
in CCPþCsA hearts compared with CCP hearts (24.54 
16.19 vs 9.19  2.22, P<.05).
Mitochondrial ROS Production
Cardioplegic arrest and reperfusion resulted in higher mi-
tochondrial ROS production rates in CCP and CCPþHA
hearts compared with that seen in non-CCP hearts
(48.2  21.4 and 45.6  16.5 vs 20.6  2.4 RFU/mg pro-
tein; P<.05 and P¼ .06, respectively), and ROS production
was not different when comparing CCPþCsA and non-CCP
hearts (23.8  1.6 vs 20.6  2.4 RFU/mg protein; P ¼ .98;
Figure 5).
Mitochondrial Bax and Bcl-2 Content
Mitochondrial Bax concentrations were increased in the
mitochondrial fraction in CCP hearts compared with those
seen in non-CCP hearts (1.06  0.33 vs 0.42  0.22 AU,
P<.05), and CCPþCsA hearts were not statistically differ-
ent than non-CCP hearts (P¼ .98). There was no difference
in Bcl-2 content among these groups (Figure 6).TABLE 1. Mitochondrial oxygen consumption (in nanomoles of
oxygen per minute per milligram of protein)
State 3
Groups State 2 Complex I Complex II Complex IV
Non-CCP 166  49 1978  279 648  65 2876  222
CCP 240  42 1439  446x 588  212 2127  626y
CCPþCsA 156  99 1816  228 571  132 2650  532
CCPþHA 209  23 851  381* 456  166z 1907  390*
Values are presented as means standard deviations (n¼ 6 for each group). For def-
initions of the study groups, see the legend for Figure 1. *P<.01, yP<.02, zP<.05,
and xP ¼ .059 versus the non-CCP group.
980 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
Aputative target for cardioprotection during reperfusion is
the MPTP.6 The MPTP remains closed throughout ischemia
but opens at the time of reperfusion,20 and the opening of this
channel ismediated by conditions such as intracellular oxida-
tive stress, ROS production, and calcium overload.6 Sus-
tained or irreversible opening of the MPTP leads to the
dissipation of mitochondrial potential, cessation of oxidative
phosphorylation,matrix swelling, and eventually outermem-
brane rupture.21MPTP opening can be a reversible event and
does not always lead to demonstrable mitochondrial swell-
ing22 and depolarization.23 Transient MPTP opening with
full cardiac functional recovery is associatedwithmild forms
of ischemia–reperfusion injury.7 Inhibition ofMPTPopening
prevents mitochondria-driven necrotic and apoptotic pro-
cesses and apoptosis-related mitochondrial dysfunction in
the postcardioplegic myocardium.3 The novel observations
of the present study include the following: (1) transient
MPTPopening occurredwithin 30minutes of reperfusion af-
ter cardioplegic arrest, andMPTP resealing ensuedwithin 30
minutes of reperfusion, and (2) precardioplegic arrest inhibi-
tion of MPTP opening by CsA prevented the occurrence of
apoptosis-relatedmitochondrial dysfunction, whereas the fa-
cilitation of MPTP opening by the Bcl-2 inhibitor HA14-1
augmented the deficit of mitochondrial respiratory chain ac-
tivity. These data suggest thatMPTPopening plays an impor-
tant role as a mediator of apoptosis-related mitochondrialFIGURE 5. Isolated mitochondrial reactive oxygen species (ROS) pro-
duction rate (RFU per minute per milligram of protein). *P< .05 and
**P ¼ .06 versus the non-CCP group. For definitions of the study groups,
see the legend for Figure 1.
ery c April 2011
FIGURE 6. A, Representative immunoblots of mitochondrial Bax, Bcl-2, and cytochrome c oxidase IV (COX IV). *P<.05 versus the non-CCP group. B,
Densitometric measurements of Bax and Bcl-2 protein content normalized to COX IV. For definitions of the study groups, see the legend for Figure 1.
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Ddysfunction after neonatal cardioplegic arrest. Although
early apoptosis-related processes are initiated (Bax translo-
cation, mitochondrial permeabilization, and cytochrome c
release),we have previously demonstrated that there is sparse
progression to completed apoptosis (<1% ofmyocytes) after
6 hours of observation in a neonatal lambmodel.24 Therefore
the constellationofmitochondrial alterationsmight represent
a stalled form of apoptosis, and the clinical reality that most
neonatal myocardial function returns in the early postopera-
tive period suggests that myocyte recovery (rather than cell
death) is the norm.
Proposed mechanisms for mitochondrial membrane per-
meabilization after ischemia–reperfusion injury include
nonspecific mitochondrial swelling, rupture of the outerThe Journal of Thoracic and Camembrane, and MPTP opening.25 The vast majority of
studies evaluating these mechanisms of mitochondrial per-
meabilization are in infarct models of lethal mitochondrial
injury with sustainedMPTP opening. In contrast, cardiople-
gic arrest results in a mild ischemia–reperfusion injury in
which recovery of myocardial function is typical and necro-
sis is rare or nonexistent.24 However, the time course of res-
toration of mitochondrial integrity after cardioplegic arrest
has not been fully studied. The present study suggests that
resealing of the MPTP is nearly complete within 30 minutes
after reperfusion and that mitochondrial electron transport
is linked to the status of mitochondrial permeabilization.
Translocation of Bax to the mitochondria is a well-
recognized proapoptotic signal that is associated withrdiovascular Surgery c Volume 141, Number 4 981
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Dmitochondrial permeabilization. Because Bax can form in
vitro multimers with pore-forming capability, it has been hy-
pothesized as amediator ofmitochondrial permeabilization in
apoptotic signalling.26 Our laboratory and others have dem-
onstrated that disruptionofmitochondrialmembrane integrity
is associated with translocation of Bax to the mitochondrial
fraction.2,27 In the present study we find evidence that Bax
might be involved in mitochondrial permeabilization based
on translocation of Bax to the mitochondrial fraction. In
contrast, inhibition of MPTP opening with CsA
administration is associated with mitochondrial preservation
and diminished Bax translocation. These data are consistent
with the concept that Bax translocation is downstream from
MPTP opening andmight participate in a feed-forward signal
to enhance mitochondrial permeabilization.28 Baxmitochon-
drial redistributionandcytochromec releasecanoccur asade-
layed process in isolated cellmodels downstream fromMPTP
opening.8 Bax (proapoptotic) and Bcl-2 (antiapoptotic) play
opposing regulatory roles in mitochondrial permeabilization.
Bax-inducedmitochondrial permeability changes can be pre-
vented by Bcl-2.29 The involvement of Bcl-2 in the control of
MPTP opening and apoptosis-relatedmitochondrial dysfunc-
tion was supported by our finding that inhibition of Bcl-2 by
HA14-1 enhanced MPTP opening, and these changes were
associated with deficits of activity in complexes I and IV
that could be prevented by inhibition of Bax translocation
with CsA.
In conclusion, our data suggest that cardioplegic arrest
and reperfusion are associated with transient mitochondrial
permeabilization of the MPTP and subsequent restoration
of mitochondrial integrity within 30 minutes. Mitochon-
drial permeabilization is associated with ROS production,
secondary Bax translocation, and dysfunctional electron
transport at complexes I and IV, with a potential amplifica-
tion role for Bax as a mediator of mitochondrial permeabi-
lization. Therefore clinical strategies that are directed to
minimize initial MPTP opening and apoptosis-related mito-
chondrial dysfunction might work in a synergistic fashion
with other more conventional therapeutic modalities
designed to minimize myocardial stunning and thereby
improve postoperative myocardial performance.
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